{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T04:11:36Z","timestamp":1789099896758,"version":"build-2803163510"},"reference-count":33,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,7]],"date-time":"2022-09-07T00:00:00Z","timestamp":1662508800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Hepatology"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.aohep.2022.100756","type":"journal-article","created":{"date-parts":[[2022,9,9]],"date-time":"2022-09-09T22:35:29Z","timestamp":1662762929000},"page":"100756","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Hepatic mir-122-3p, mir-140-5p and mir-148b-5p expressions are correlated with cytokeratin-18 serum levels in MAFLD"],"prefix":"10.1016","volume":"27","author":[{"given":"Guillermo N.","family":"L\u00f3pez-S\u00e1nchez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Montalvo-Jav\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayra","family":"Dom\u00ednguez-Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Antuna-Puente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredy O.","family":"Beltr\u00e1n-Anaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Hidalgo-Miranda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norberto C.","family":"Ch\u00e1vez-Tapia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Misael","family":"Uribe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Nu\u00f1o- L\u00e1mbarri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.aohep.2022.100756_bib0001","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement","volume":"73","author":"Eslam","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2022.100756_bib0002","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.dsx.2020.05.019","article-title":"From non-alcoholic fatty liver disease (NAFLD) to metabolic-associated fatty liver disease (MAFLD): A journey over 40 years","volume":"14","author":"Kuchay","year":"2020","journal-title":"Diabetes Metab Syndr"},{"key":"10.1016\/j.aohep.2022.100756_bib0003","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003100","article-title":"Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of population-based observational studies","volume":"17","author":"Jarvis","year":"2020","journal-title":"PLoS Med"},{"key":"10.1016\/j.aohep.2022.100756_bib0004","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgac321","article-title":"Global prevalence and clinical characteristics of metabolic-associated fatty liver disease: a meta-analysis and systematic review of 10 739 607 individuals","author":"Chan","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.aohep.2022.100756_bib0005","doi-asserted-by":"crossref","first-page":"e573","DOI":"10.1016\/j.cgh.2021.02.030","article-title":"Estimating global prevalence of metabolic dysfunction-associated fatty liver disease in overweight or obese adults","volume":"20","author":"Liu","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.aohep.2022.100756_bib0006","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.metabol.2015.12.012","article-title":"The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)","volume":"65","author":"Buzzetti","year":"2016","journal-title":"Metabolism"},{"key":"10.1016\/j.aohep.2022.100756_bib0007","first-page":"2018","article-title":"Relationship between serum cytokeratin-18, control attenuation parameter, nafld fibrosis score, and liver steatosis in nonalcoholic fatty liver disease","author":"Kosasih","year":"2018","journal-title":"Int J Hepatol"},{"key":"10.1016\/j.aohep.2022.100756_bib0008","doi-asserted-by":"crossref","DOI":"10.12669\/pjms.36.3.1674","article-title":"Association of liver biomarkers and cytokeratin-18 in Nonalcoholic fatty liver disease patients","volume":"36","author":"Altaf","year":"2020","journal-title":"Pak J Med Sci"},{"key":"10.1016\/j.aohep.2022.100756_bib0009","article-title":"Accuracy of cytokeratin 18 (M30 and M65) in detecting non-alcoholic steatohepatitis and fibrosis: a systematic review and meta-analysis","volume":"15","author":"Lee","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.aohep.2022.100756_bib0010","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/978-3-319-48382-5_19","article-title":"Non-alcoholic fatty liver disease","volume":"960","author":"Engin","year":"2017","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.aohep.2022.100756_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.aohep.2020.04.012","article-title":"Non-alcoholic fatty liver disease and microRNAs expression, how it affects the development and progression of the disease","volume":"21","author":"L\u00f3pez-S\u00e1nchez","year":"2021","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.aohep.2022.100756_bib0012","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.3748\/wjg.v24.i27.2949","article-title":"MicroRNAs in the prognosis and therapy of colorectal cancer: from bench to bedside","volume":"24","author":"To","year":"2018","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.aohep.2022.100756_bib0013","doi-asserted-by":"crossref","unstructured":"The International Liver CongressTM 2020, London, UK. J Hepatol 2020;72:ii. https:\/\/doi.org\/10.1016\/S0168-8278(19)30682-8.","DOI":"10.1016\/S0168-8278(19)30618-X"},{"key":"10.1016\/j.aohep.2022.100756_bib0014","doi-asserted-by":"crossref","first-page":"2884","DOI":"10.1172\/JCI63455","article-title":"MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis","volume":"122","author":"Tsai","year":"2012","journal-title":"J Clinical Investigation"},{"key":"10.1016\/j.aohep.2022.100756_bib0015","doi-asserted-by":"crossref","first-page":"3629","DOI":"10.2174\/0929867311320290009","article-title":"MicroRNA miR-122 as a therapeutic target for oligonucleotides and small molecules","volume":"20","author":"Thomas","year":"2013","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.aohep.2022.100756_bib0016","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1080\/13813455.2019.1640744","article-title":"The miR-122 inhibition alleviates lipid accumulation and inflammation in NAFLD cell model","volume":"127","author":"Hu","year":"2021","journal-title":"Arch Physiol Biochem"},{"key":"10.1016\/j.aohep.2022.100756_bib0017","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2022.100756_bib0018","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","article-title":"Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention","volume":"15","author":"Younossi","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.aohep.2022.100756_bib0019","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1002\/hep.30251","article-title":"Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis","volume":"69","author":"Younossi","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2022.100756_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.aohep.2021.100651","article-title":"Laparoscopic cholecystectomy: Histopathological analysis of metabolic associated fatty liver disease and fibrosis","volume":"27","author":"Rodr\u00edguez-Antonio","year":"2022","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.aohep.2022.100756_bib0021","first-page":"201","article-title":"Apoptosis in nonalcoholic fatty liver disease: diagnostic and therapeutic implications","volume":"5","author":"Alkhouri","year":"2014","journal-title":"Http:\/\/DxDoiOrg\/101586\/Egh116"},{"key":"10.1016\/j.aohep.2022.100756_bib0022","doi-asserted-by":"crossref","first-page":"837","DOI":"10.5604\/16652681.1171767","article-title":"Correlation between serum cytokeratin-18 and the progression or regression of non-alcoholic fatty liver disease","volume":"14","author":"Kawanaka","year":"2015","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.aohep.2022.100756_bib0023","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3350\/cmh.2019.0011","article-title":"The fibrogenic process and the unleashing of acute-on-chronic liver failure","volume":"26","author":"L\u00f3pez-S\u00e1nchez","year":"2020","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.aohep.2022.100756_bib0024","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1097\/MPG.0b013e3181e376be","article-title":"Serum levels of CK18 M30 and leptin are useful predictors of steatohepatitis and fibrosis in paediatric NAFLD","volume":"51","author":"Fitzpatrick","year":"2010","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.aohep.2022.100756_bib0025","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1016\/j.jaci.2017.08.034","volume":"141","author":"Lu","year":"2018","journal-title":"J Aller Clin Immunol"},{"key":"10.1016\/j.aohep.2022.100756_bib0026","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.cmet.2019.07.011","article-title":"Extracellular miRNAs: from biomarkers to mediators of physiology and disease","volume":"30","author":"Mori","year":"2019","journal-title":"Cell Metab"},{"key":"10.1016\/j.aohep.2022.100756_bib0027","doi-asserted-by":"crossref","first-page":"801","DOI":"10.2217\/fon-2018-0812","article-title":"Why have microRNA biomarkers not been translated from bench to clinic?","volume":"15","author":"Saliminejad","year":"2019","journal-title":"Future Oncol"},{"key":"10.1016\/j.aohep.2022.100756_bib0028","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s10020-019-0085-2","article-title":"miR-122 promotes hepatic lipogenesis via inhibiting the LKB1\/AMPK pathway by targeting Sirt1 in non-alcoholic fatty liver disease","volume":"25","author":"Long","year":"2019","journal-title":"Mol Med"},{"key":"10.1016\/j.aohep.2022.100756_bib0029","doi-asserted-by":"crossref","first-page":"7466","DOI":"10.1038\/ncomms8466","article-title":"A metabolic stress-inducible miR-34a-HNF4\u03b1 pathway regulates lipid and lipoprotein metabolism","volume":"6","author":"Xu","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.aohep.2022.100756_bib0030","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.clnu.2018.09.024","article-title":"Circulating microRNAs and adipokines as markers of metabolic syndrome in adolescents with obesity","volume":"38","author":"HA","year":"2019","journal-title":"Clin Nutr"},{"key":"10.1016\/j.aohep.2022.100756_bib0031","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1002\/eji.201747132","article-title":"The role of the miR-148\/-152 family in physiology and disease","volume":"47","author":"Friedrich","year":"2017","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.aohep.2022.100756_bib0032","doi-asserted-by":"crossref","first-page":"e226","DOI":"10.1038\/emm.2016.3","article-title":"miR-148a is a downstream effector of X-box-binding protein 1 that silences Wnt10b during adipogenesis of 3T3-L1 cells","volume":"48","author":"Cho","year":"2016","journal-title":"Exp Mol Med"},{"key":"10.1016\/j.aohep.2022.100756_bib0033","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.625566","article-title":"MiR-148b-3p regulates the expression of dtymk to drive hepatocellular carcinoma cell proliferation and metastasis","volume":"11","author":"He","year":"2021","journal-title":"Front Oncol"}],"container-title":["Annals of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1665268122000989?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1665268122000989?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T10:44:49Z","timestamp":1761648289000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1665268122000989"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S1665268122000989"],"URL":"https:\/\/doi.org\/10.1016\/j.aohep.2022.100756","relation":{},"ISSN":["1665-2681"],"issn-type":[{"value":"1665-2681","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hepatic mir-122-3p, mir-140-5p and mir-148b-5p expressions are correlated with cytokeratin-18 serum levels in MAFLD","name":"articletitle","label":"Article Title"},{"value":"Annals of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.aohep.2022.100756","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Fundaci\u00f3n Cl\u00ednica M\u00e9dica Sur, A.C. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}],"article-number":"100756"}}